*ST目药(600671) - 2024 Q2 - 季度业绩预告

Performance Forecast Summary The company expects to continue incurring losses in the first half of 2024, but with a narrowed loss range for net profit attributable to shareholders and non-recurring adjusted net profit Key Financial Indicators | Indicator (Unit: RMB million) | H1 2024 (Estimated) | H1 2023 (Prior Period) | | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -22.4663 to -17.4663 | -23.4210 | | Net Profit After Deducting Non-Recurring Gains/Losses | -26.0104 to -21.0104 | -21.1039 | - Compared to the prior year, net profit attributable to parent company shareholders is expected to reduce losses by RMB 0.9547 million to RMB 5.9547 million, indicating a narrowed loss[12][6] Analysis of Performance Change Despite year-over-year revenue growth, the company's gross profit remains insufficient to cover period expenses due to ongoing policy impacts like medical insurance cost control and volume-based procurement, compounded by increased sales and administrative costs supporting business expansion - The company achieved year-over-year growth in operating revenue, but product gross profit is insufficient to cover period expenses due to policies such as medical insurance cost control, consistency evaluation, and volume-based procurement[6] - To support expanded business layout and adjusted sales policies, the company strengthened sales and operational management, leading to a year-over-year increase in management costs, including personnel salaries and property rental amortization[6] Risk Warning and Other Disclosures The company clarifies that this performance forecast is a preliminary estimate by the finance department, unaudited by certified public accountants, and final financial data will be based on the officially disclosed 2024 semi-annual report, advising investors to be aware of associated investment risks - This performance forecast represents a preliminary estimate by the company's finance department based on professional judgment, and has not yet been audited or reviewed by certified public accountants[7][13] - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[7][16] - The final accurate financial data will be subject to the company's officially disclosed 2024 semi-annual report, and investors are advised to be aware of investment risks[17]